Objective  To conduct an overview of systematic reviews/Meta-analyses on Xuebijing injection for sepsis, to comprehensively evaluate their methodological quality, reporting quality, and evidence quality, and to provide an evidence-based foundation for clinical practice and guideline development.

Methods  Both Chinese and international databases were searched, including CNKI, WanFang, VIP, SinoMed, PubMed, Embase, Cochrane Library, Web of Science, to identify systematic reviews/Meta-analyses on Xuebijing injection for sepsis published up to October 20, 2025. The methodological quality was assessed using the AMSTAR 2 tool, reporting quality was evaluated using the PRISMA 2020 checklist, and the GRADE system was applied for evidence grading.

Results  A total of 16 systematic reviews/Meta-analyses published between 2010 and 2023 were included. Primary outcome measures included mortality, APACHE II scores, inflammatory factors, and coagulation parameters. AMSTAR 2 results indicated an overall low to very low methodological quality, with critical flaws primarily focused on the lack of registered protocols (Item 2). PRISMA 2020 results showed an average reporting completeness of 57.41%, with >50% deficiency rates for items such as other results analyses, registration and protocol, and conflicts of interest. GRADE assessment indicated that the evidence for mortality, APACHE II scores, and safety was of moderate quality.

Conclusion  Xuebijing injection combined with conventional therapy may reduce mortality, improve organ function, and alleviate inflammatory response in sepsis patients, with a favorable safety profile. However, the quality of existing evidence is limited, necessitating further validation through high-quality, multi-center randomized controlled trials and standardized systematic reviews.

1.Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315(8): 762-774. DOI: 10.1001/jama.2016.0288.

2.Font MD, Thyagarajan B, Khanna AK. Sepsis and Septic Shock-Basics of diagnosis, pathophysiology and clinical decision making[J]. Med Clin North Am, 2020, 104(4): 573-585. DOI: 10.1016/j.mcna.2020.02.011.

3.Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990—2017: analysis for the global burden of disease study[J]. Lancet, 2020, 395(10219): 200-211. DOI: 10.1016/S0140-6736(19)32989-7.

4.De Backer D, Deutschman CS, Hellman J, et al. Surviving sepsis campaign research priorities 2023[J]. Crit Care Med, 2024, 52(2): 268. DOI: 10.1097/CCM.0000000000006135.

5.丁伟超, 陈娟, 姬晓航, 等. 血必净注射液通过抑制HIF-1α/p38 MAPK/NF-κB信号通路对脓毒症相关急性呼吸窘迫综合征的保护作用[J]. 中华急诊医学杂志, 2024, 33(8): 1140-1150. [Ding WC, Chen J, Ji XH, et al. Protective effect of Xuebijing injection on sepsis-associated acute respiratory distress syndrome by suppressing the HIF-1α/p38 MAPK/NF-κB signaling pathway[J]. Chinese Journal of Emergency Medicine, 2024, 33(8): 1140-1150.] DOI: 10.3760/cma.j.issn.1671-0282.2024.08.011.

6.Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both[J]. BMJ, 2017, 358: j4008. DOI: 10.1136/bmj.j4008.

7.Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews[J]. BMJ, 2021, 372: n160. DOI: 10.1136/bmj.n160.

8.Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. an overview of the GRADE approach and grading quality of evidence about interventions[J]. Allergy, 2009, 64(5): 669-677. DOI: 10.1111/j.1398-9995.2009.01973.x.

9.刘静婷, 曹学东, 李会芳. 血必净注射液治疗脓毒症有效性的Meta分析[J]. 山西中医药大学学报, 2021, 22(1): 12-18. [Liu JT, Cao XD, Li HF. Meta-analysis of the effectiveness of Xuebijing injection in the treatment of sepsis[J]. Journal of Shanxi University of Chinese Medicine, 2021, 22(1): 12-18.] DOI: 10.19763/j.cnki.2096-7403.2021.01.04.

10.张嘉雯, 贺园莉, 史阳, 等. 血必净注射液治疗脓毒症血管内皮损伤有效性及安全性的Meta分析[J]. 海南医学院学报, 2021, 27(12): 910-917. [Zhang JW, He YL, Shi Y, et al. Efficacy and safety of Xuebijing injection in the treatment of vascular endothelial injury in sepsis patients: a Meta-analysis[J]. Journal of Hainan Medical University, 2021, 27(12): 910-917.] DOI: 10.13210/j.cnki.jhmu.20200831.007.

11.李嘉彤, 邵旭鹏, 谢娜, 等. 血必净注射液治疗脓毒症心功能障碍有效性和安全性的Meta分析[J]. 中国中医急症, 2023, 32(2): 189-194. [Li JT, Shao XP, Xie N, et al. Meta-analysis on the efficacy and safety of Xuebijing injection in the treatment of sepsis-induced myocardial dysfunction[J]. Journal of Emergency in Traditional Chinese Medicine, 2023, 32(2): 189-194.] DOI: 10.3969/j.issn.1004-745X.2023.02.001.

12.吴玉娇, 张晶, 漆立军. 血必净注射液治疗脓毒症临床疗效和安全性的Meta分析[J]. 中华危重病急救医学, 2020, 32(6): 691-695. [Wu YJ, Zhang J, Qi LJ. Clinical efficacy and safety of Xuebijing injection on sepsis: a Meta-analysis[J]. Chinese Critical Care Medicine, 2020, 32(6): 691-695.] DOI: 10.3760/cma.j.cn121430-20200427-00475.

13.李娜, 蒋林伟, 俞璐, 等. 血必净注射液治疗脓毒症的系统评价[J]. 中国现代药物应用, 2013, 7(22): 8-11. [Li Na, Jiang LW, Yu L, et al. Systematic review of Xuebijing injection for the treatment of sepsis[J]. Chinese Journal of Modern Drug Application, 2013, 7(22): 8-11.] DOI: 10.14164/j.cnki.cn11-5581/r.2013.22.222.

14.胡晶, 商洪才, 李晶, 等. 血必净注射液治疗脓毒症的系统评价[J]. 解放军医学杂志, 2010, 35(1): 9-12. [Hu J, Shang HC, Li J, et al. XUEBIJING injection for sepsis: a comprehensive review[J].Medical Journal of Chinese People's Liberation Army, 2010, 35(1): 9-12.] https://c.wanfangdata.com.cn/magazine/jfjyxzz.

15.孙春丽, 庄燕, 王醒. 血必净注射液治疗脓毒症的Meta分析 [J]. 中国中医急症, 2012, 21(3): 411-413. [Sun CL, Zhuang  Y, Wang X. Meta-analysis of Xuebijing injection in the treatment of sepsis[J]. Journal of Emergency in Traditional Chinese Medicine, 2012, 21(3): 411-413.] DOI: 10.3969/j.issn.1004-745X.2012.03.038.

16.李国政, 肖扬, 朱家旺, 等. 血必净注射液治疗脓毒性休克的系统评价[J]. 中国中医急症, 2016, 25(5): 834-838. [Li GZ, Xiao Y, Zhu JW, et al. Systematic review of Xuebijing injection for the treatment of septic shock[J]. Journal of Emergency in Traditional Chinese Medicine, 2016, 25(5): 834-838.] DOI: 10.3969/j.issn.1004-745X.2016.05.025.

17.许玉琼, 耿焱, 童华生, 等. 血必净注射液提高脓毒症患者生存率的Meta分析[J]. 中医药临床杂志, 2014, 26(5): 456-460. [Xu YQ, Gen Y, Tong HS, et al. Meta-analysis: Xuebijing injection improves survival rate in sepsis patients[J]. Clinical Journal of Traditional Chinese Medicine, 2014, 26(5): 456-460.] DOI: 10.16448/j.cjtcm.2014.05.037.

18.刘峻溪, 吴彩军, 赵艺源子, 等. 血必净注射液对脓毒症乳酸清除效果的Meta分析[J]. 中国中西医结合急救杂志, 2024, 31(2): 134-140. [Liu JX, Wu CJ, Zhao YYZ, et al. Meta-analysis of the effect of Xuebijing injection on lactic acid clearance in sepsis[J]. Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care, 2024, 31(2): 134-140.]DOI: 10.3969/j.issn.1008-9691.2024.02.002.

19.孙红双, 吕菁君, 魏捷, 等. 血必净注射液对脓毒症患者凝血功能影响分析[J]. 临床药物治疗杂志, 2015, 13(4): 41-46. [Sun HS, Lyu JJ, Wei J, et al. Effect of Xuebijing injection on coagulation function in patients with sepsis: a systematic review and Meta-analysis[J]. Clinical Medication Journal, 2015, 13(4): 41-46.] DOI: 10.3969/j.issn.1672-3384.2015.04.010.

20.凌梦雨, 邱逢意, 许飚, 等. 血必净注射液对脓毒性休克患者凝血功能障碍的Meta分析[J]. 中国民族民间医药, 2023, 32(5): 105-110. [Ling MY, Qiu FY, Xu B, et al. Meta-analysis on the coagulation function of Xuebijing injection in the treatment of sepsis shock[J]. Chinese Journal of Ethnomedicine and Ethnopharmacy, 2023, 32(5): 105-110.] https://d.wanfangdata.com.cn/periodical/CiBQZXJpb2RpY2FsQ0hJU29scjkyMDI2MDIwMjE0MTYxMhITemdtem1qeXl6ejIwMjMwNTAyNhoIY3p0cGFha3g%3D.

21.周仙仕, 唐光华, 李俊, 等. 血必净降低脓毒性休克患者病死率的系统评价[J]. 中华中医药学刊, 2016, 34(9): 2161-2164. [Zhou XS, Tang GH, Li J, et al. Xuebijing injection reducing mortality of septic shock patients: a systematic review and meta-analysis[J]. Chinese Archives of Traditional Chinese Medince, 2016, 34(9): 2161-2164.] DOI: 10.13193/j.issn.1673-7717.2016.09.032.

22.Shi H, Hong Y, Qian J, et al. Xuebijing in the treatment of patients with sepsis[J]. Am J Emerg Med, 2017, 35(2): 285-291. DOI: 10.1016/j.ajem.2016.11.007.

23.Li C, Wang P, Zhang L, et al. Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: a Meta-analysis of randomized controlled trials[J]. J Ethnopharmacol, 2018, 224: 512-521. DOI: 10.1016/j.jep.2018.05.043.

24.Hou SY, Feng XH, Lin CL, et al. Efficacy of Xuebijing for coagulopathy in patients with sepsis[J]. Saudi Med J, 2015, 36(2): 164-169. DOI: 10.15537/smj.2015.2.9895.

25.陈薇, 方赛男, 刘建平. 基于证据体的中医药临床证据分级标准建议[J]. 中国中西医结合杂志, 2019, 39(3): 358-364. [Chen W, Fang SN, Liu JP. Suggestions on grading standards for clinical evidence of traditional Chinese medicine based on evidence body[J]. Journal of Integrative Traditional Chinese and Western Medicine, 2019, 39(3): 358-364.] https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201903021.htm.

26.洪晓阳, 裴海鹏, 陈红超, 等. 连续性血液净化联合血必净治疗脓毒血症的效果及对患者炎性因子水平、血流动力学指标的影响[J]. 临床医学研究与实践, 2021, 6(18): 78-80. [Hong XY, Pei HP, Chen HC, et al. Effect of continuous blood purification combined with Xuebijing in the treatment of sepsis and its influence on inflammatory factors levels and hemodynamic parameters[J]. Clinical Medical Research and Practice, 2021, 6(18): 78-80.] DOI: 10.19347/j.cnki.2096-1413.202118026.

27.刘英杰, 谭旭宏, 吴琴琴, 等. 静脉血液滤过模式血液净化联合血必净对脓毒症患者免疫功能和炎症因子的干预研究[J]. 中医临床研究, 2022, 14(4): 66-69. [Liu YJ, Tan  XH, Wu QQ, et al. A study on intervening immune function and inflammatory factors in patients with sepsis by CVVH mode blood purification plus the Xuebijing injection[J]. Clinical Research of Traditional Chinese Medicine, 2022, 14(4): 66-69.] DOI: 10.3969/j.issn.1674-7860.2022.04.016.

28.霍小艳, 丁帅, 吴琼, 等. 血必净注射液对重症脓毒症患者炎性因子水平及凝血功能指标的影响[J]. 临床医学研究与实践, 2023, 8(1): 121-123. [Huo XY, Ding S, Wu Q, et al. Effects of Xuebijing injection on inflammatory factors levels and coagulation function indexes in patients with severe sepsis[J]. Clinical Research and Practice, 2023, 8(1): 121-123.] DOI: 10.19347/j.cnki.2096-1413.202301033.

29.吴忧, 白倩, 葛星峰, 等. 血必净注射液对感染性多器官功能障碍综合征患者肝肾功能及炎性因子的影响[J]. 黑龙江医学, 2025, 49(1): 58-60. [Wu Y, Bai Q, Ge XF, et al. Effect of Xuebijing injection on liver and kidney function and inflammatory factors in patients with infectious multiple organ dysfunction syndrome[J]. Heilongjiang Medical Journal, 2025, 49(1): 58-60.] DOI: 10.3969/j.issn.1004-5775.2025.01.016.

30.Kang XF, Lu XL, Bi CF, et al. Xuebijing injection protects sepsis induced myocardial injury by mediating TLR4/NF-κB/IKKα and JAK2/STAT3 signaling pathways[J]. Aging (Albany NY), 2023, 15(16): 8501-8517. DOI: 10.18632/aging.204990.

31.杨兴才, 韦红, 郑天虹, 等. 血必净注射液对脓毒症血管内皮损伤微循环障碍患者治疗及器官功能保护作用的临床研究[J]. 中国综合临床, 2017, 33(9): 812-818. [Yang XC, Wei H, Zheng TH, et al. Clinical study of theraprutic effect of Xuebijing injection on the treatment of vascular endothelial cell injury, microcirculation disorder and organ diysfunction in patients with sepsis[J]. Clinical Medicine of China, 2017, 33(9): 812-818.] DOI: 10.3760/cma.j.issn.1008-6315.2017.09.010.

32.归咏刚. 血必净对脓毒症大鼠单核细胞组织因子及凝血功能的影响[D]. 天津: 天津医科大学, 2009. DOI: 10.7666/d.y1553030.

33.Liu S, Yao C, Xie J, et al. Effect of an herbal-based injection on 28-day mortality in patients with sepsis: the EXIT-SEP randomized clinical trial[J]. JAMA Intern Med, 2023, 183(7): 647-655. DOI: 10.1001/jamainternmed.2023.0780.

34.Lou X, Chen H, Shi N, et al. Treatment effects of Xuebijing injection in patients with sepsis by clinical phenotype: a post hoc analysis of the EXIT-SEP trial[J]. EClinicalMedicine, 2025, 86: 103341. DOI: 10.1016/j.eclinm.2025.103341.

35.Thomas ET, Heneghan C, 孟玲慧. 偏倚一览: 选择性报告结果偏倚[J]. 英国医学杂志（中文版）, 2022, 25(6): 350-352. [Thomas ET, Heneghan C, Meng LH. Catalogue of bias: selective outcome reporting bias[J]. Chinese Edition of BMJ, 2022, 25(6): 350-352.] DOI: 10.3760/cma.j.issn.1007-9742.2022.06.113.

36.Hansen C, Lundh A, Rasmussen K, et al. Financial conflicts of interest in systematic reviews: associations with results, conclusions, and methodological quality[J]. Cochrane Database Syst Rev, 2019, 8(8): MR000047. DOI: 10.1002/14651858.MR000047.pub2.

37.黄慧瑶, 孟鑫雨, 祝琦, 等. 临床试验亚组分析结果可靠性评价及监管决策影响[J]. 中国新药杂志, 2022, 31(8): 778-783. [Huang HY, Meng XY, Zhu Q, et al. Credibility evaluation of subgroup analysis in clinical trials and its impact on regulatory decision[J]. Chinese Journal of New Drugs, 2022, 31(8): 778-783.] DOI: 10.3969/j.issn.1003-3734.2022.08.010.

38.陈茜, 杨雁. 随机对照试验设计要点[J]. 中华糖尿病杂志, 2021, 13(6): 645-648. [Chen Q, Yang Y. Key points of randomized controlled trial design[J]. Chinese Journal of Diabetes Mellitus, 2021, 13(6): 645-648.] DOI: 10.3760/cma.j.cn115791-20210331-00185.

39.姚阿玲. 发表偏倚对Meta分析结果影响的模拟研究[D]. 广州: 南方医科大学, 2015. DOI: 10.7666/d.Y2911410.